635323-95-4

Usage

Uses

Used in Pharmaceutical Industry:
F₁₅₅₉₉ is used as a therapeutic agent for targeting the dopamine D3 receptor subtype, due to its high affinity and selectivity. This makes it a potential candidate for the treatment of various neurological and psychiatric disorders.
Used in Neurological Disorders Treatment:
F₁₅₅₉₉ is used as a potential drug for conditions such as schizophrenia, due to its interaction with the dopamine D3 receptor subtype, which is implicated in the pathophysiology of the disorder.
Used in Substance Abuse Treatment:
F₁₅₅₉₉ is used as a potential therapeutic agent for substance abuse, as its action on the dopamine D3 receptor subtype may help in managing addiction-related behaviors and cravings.
Used in Research and Development:
F₁₅₅₉₉ is used in research for further investigating its potential as a drug candidate, exploring its pharmacological properties, and understanding its mechanism of action in treating neurological and psychiatric disorders.

Upstream product

• 448920-98-7 2-[1-[(3-chloro-4-fluorophenyl)carbonyl]-4-fluoropiperidin-4-yl]-2-hydroxyacetonitrile 
• 930272-60-9 (5-methylpyrimidin-2-yl)methanamine 
• 1346542-72-0 5-methylpyrimidine-2-methylamine dihydrochloride 
• 65055-17-6 3-chloro-4-fluorobenzoyl chloride 
• 1346542-72-0 (5-methylpyrimidin-2-yl)methanamine hydrochloride 
• 403-16-7 3-chloro-4-fluorobenzoic acid 
• 223632-64-2 1-[(3-chloro-4-fluorophenyl)carbonyl]piperidin-4-one 
• 448920-97-6 6-[(3-chloro-4-fluorophenyl)carbonyl]-1-oxa-6-azaspiro[2.5]octane-2-carbonitrile 

Relevant academic research and scientific papers

Deuterium-Substituted Pyridin- And Pyrimidin-2-yl-Methylamine Compounds

Described are deuterium-substituted pyridin- and pyrimidin-2-yl-methylamine compounds of structural Formula (I), which are agonists of 5-hydroxytryptamine receptors. Also described are pharmaceutical compositions comprising the deuterium-substituted pyridin- and pyrimidin-2-yl-methylamine compounds, and methods of use thereof.

METHOD FOR PREPARING (3-CHLORO-4-FLUOROPHENYL)-(4-FLUORO-4-{[(5METHYL-PYRIMIDIN-2-YLMETHYL)-AMINO]-METHYL}-PIPERIDIN-1-YL)-METHANONE AND NOVEL INTERMEDIATE PYRIMIDINE DERIVATIVES

The present invention concerns the method for preparing (3-chloro-4-fluorophenyl)-(4-fluoro-4-{[(5-methyl-pyrimidin-2- ylmethyl)-amino]-methyl}-piperidin-1-yl)-methanone of formula (II) by condensation between 5-methyl-pyrimidin-2-methylamine of formula (

High-efficacy 5-HT1A agonists for antidepressant treatment: A renewed opportunity

We report the discovery of novel 5-HT1A receptor agonists and describe the process that led to the antidepressant candidate 9 (F 15599). 9 has nanomolar affinity for 5-HT1A binding sites and is over 1000-fold selective with respect to the other 5-HT1 receptor subtypes, 5-HT2-7 receptor families, and also numerous GPCRs, transporters, ion channels, and enzymes. In a cellular model of signal transduction, 9 activates h5-HT1A receptors with an efficacy superior to that of the prototypical 5-HT1A agonist (±)-8-OH-DPAT and comparators undergoing clinical trials. After acute oral administration in rats, 9 totally reverses immobility in the forced swimming test and produces behaviors characteristic of 5-HT1A receptor activation. However, these effects occurred at widely separated doses, suggesting that 9 discriminates between distinct populations of 5-HT1A receptors. While the clinical relevance of these observations is still unknown, this opens new perspectives for the treatment of depressive disorders.

Novel aryl-[4-halo-4(heteroarylmethylamino)-methyl]-piperidin-1-1yl]-methanone derivatives, methods for production and use thereof as medicaments

The invention relates to compounds of general formula (1) in which X and Y=a carbon with a bonded hydrogen atom (CH) or a nitrogen atom, A=a methyl, fluoromethyl, cyano, hydroxyl, methoxy group, or a chlorine or fluorine atom on condition that when A=meth